OrbiMed

Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.

Ottimo Pharma focuses on creating pioneering cancer treatments for solid tumors, specifically through its lead program, Jankistomig, a bi-functional antibody targeting immune checkpoints and angiogenesis. The company aims to enhance treatment outcomes and alleviate healthcare burdens by advancing this dual-pathway approach.

Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

TriSalus Life Sciences, based in Westminster, Colorado, focuses on developing innovative drug delivery technologies and immune-oncology therapeutics aimed at improving treatment outcomes for challenging cancers, particularly liver and pancreatic cancer. Founded in 2009, the company specializes in precision infusion systems designed for interventional radiology. Its product offerings include Pressure Enabled Drug Delivery (PEDD) systems, which utilize a unique expandable tip catheter to deliver embolic agents while minimizing damage to healthy tissues. The Surefire infusion systems, including various models for lobar, segmental, and super-selective infusions, aim to enhance tumor uptake through controlled pressure and blood flow management. Additionally, TriSalus is advancing an investigational therapy, nelitolimod, which has shown promise in enhancing immune response against liver tumors. The company continues to innovate with devices like the TriNav, which employs SmartValve technology to optimize drug delivery.

Shenluo Medical manufactures functional neural implantable medical devices.

Arcatron Mobility is a medical device startup established in June 2015 by four engineers from NIT Calicut, focusing on creating innovative mobility solutions for individuals with limited mobility, particularly the elderly. With over 110 million elderly citizens in India needing assistance with daily activities such as bathing and walking, the demand for quality mobility aids is growing, driven by factors like aging, spinal cord injuries, and obesity. Arcatron addresses the gap in the market for affordable and high-quality mobility devices, offering products such as smart wheelchairs that enable safe access to bathrooms and other areas. These devices are enhanced with integrated applications that allow family members to track and monitor users, thereby promoting independence and safety. Arcatron aims to establish itself as a leader in the domestic market and gain recognition as a trusted global medical device brand.

Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on restless leg syndrome. Its innovative device utilizes neural circuitry to alleviate symptoms and promote undisturbed sleep, empowering patients to better manage their chronic medical conditions.

Vicore Pharma is a clinical-stage pharmaceutical company dedicated to developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company's lead drug candidate, C21, is a small molecule angiotensin II type 2 receptor agonist currently in phase 2a development and has received orphan drug designation in both the EU and the US. C21 is also being explored for potential applications in other rare diseases associated with the AT2 receptor. In addition to its pharmacological efforts, Vicore Pharma is developing Almee, an investigational medical device that employs cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. The company operates from Astra Zeneca’s Bioventurehub in Mölndal.

Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Insmed Incorporated is a global biopharmaceutical company dedicated to improving the lives of patients with serious and rare diseases. Its flagship product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the United States for treating Mycobacterium avium complex (MAC) lung disease, targeting adult patients who have limited or no alternative treatment options. MAC lung disease is a rare and potentially fatal infection that can lead to significant lung damage. In addition to ARIKAYCE, Insmed's clinical pipeline features Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which shows promise for treating non-cystic fibrosis bronchiectasis and other inflammatory conditions. Another candidate in development is INS1009, an inhaled formulation of a treprostinil prodrug aimed at addressing rare pulmonary disorders, including pulmonary arterial hypertension.

Adaptive Biotechnologies is a commercial-stage company focused on advancing immune-driven medicine by leveraging the adaptive immune system's biology to enhance disease diagnosis and treatment. Founded in 2009 and headquartered in Seattle, Washington, the company offers the clonoSEQ diagnostic test, which is authorized by the FDA for detecting and monitoring minimal residual disease in patients with specific blood cancers, including multiple myeloma and certain forms of leukemia. Additionally, Adaptive provides immunoSEQ services and kits for research purposes, aiding in the discovery of prognostic and diagnostic signals. The company is engaged in strategic collaborations with organizations such as Genentech and Microsoft to develop innovative therapies and diagnostic tools. Its offerings cater to life sciences research, clinical diagnostics, and drug discovery sectors.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.

Edge Medical Robotics, Inc. was founded in Longgang, Shenzhen, China on May 4, 2017. It is committed to researching and promoting most advanced smart equipment in the world，polishing the ultimate product with the spirit of pursuing excellence and fineness, improving surgical safety and treatment efficacy, and contributing to uprising the level of social health.

LifeCell is a private stem cell bank that brings the concept of umbilical cord stem cell banking to India. Set up in the year 2004, LifeCell started out as an umbilical cord stem cell banking company and has now grown to become a comprehensive stem cells solutions provider with a complete spectrum of services including multi-service stem cell banking, R&D, stem cell clinical trials, and stem cell therapy. Based in Chennai, LifeCell has a spread over 100 service centers in India and the GCC countries.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focused on creating and commercializing human tissue-based products for regenerative medicine and vascular surgery. The company specializes in designing acellular extracellular matrices, which are crafted in vitro from banked vascular smooth muscle cells and decellularized to prevent rejection. These products serve as tissue-engineered grafts for patients requiring vascular repair or replacement. Humacyte's innovative approach aims to provide universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while enhancing patient care and transforming medical practices. Founded in 2004, the company is committed to advancing solutions for vascular diseases and the replacement of anatomical conduits.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.

Rimag is a Shenzhen-based company specializing in medical imaging services. Founded in 2014, it operates medical imaging centers that provide examination and diagnostic services, including MRI, CT, PET, X-ray, ultrasound, and mammography. In addition to its imaging center operations, Rimag is involved in the development of relevant cloud technology and the training of professionals in the field. The company generates revenue through its comprehensive range of services, including Imaging Center Services, Imaging Solution Services, and Rimag Cloud Services.

Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Owlet Baby Care Inc. specializes in developing and manufacturing innovative monitoring solutions for infants, focusing on providing parents with real-time insights into their child's health. Founded in 2012 and based in Lehi, Utah, the company offers a range of products, including the Owlet Smart Sock, which tracks an infant's heart rate and oxygen levels while sleeping, alerting parents to any concerns. Additionally, the Owlet Cam allows parents to monitor their baby through their smartphones with high-definition clarity. The Owlet Monitor Duo combines the functionalities of the Smart Sock and the Cam for comprehensive monitoring. The company also provides the Owlet Dream Lab, an interactive program aimed at helping parents establish healthy sleep habits for their infants. Owlet's products are available for purchase online, ensuring accessibility for parents seeking peace of mind regarding their child's well-being.

Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

EDDA Technology specializes in computer-assisted solutions for patient care management, focusing on enhancing the efficiency and effectiveness of imaging-guided cancer treatment. The company has developed the IQQA platform, which provides innovative imaging solutions that improve workflow and patient care in various surgical contexts, including open, minimally invasive, and robotic surgeries. The platform promotes a patient-specific and disease-targeted approach, facilitating a multidisciplinary strategy for cancer treatment. It supports the entire surgical process, including pre-surgical planning and simulation, intra-operative guidance and monitoring, post-operative follow-up, and training. By enabling advanced clinical applications such as automated volumetric organ segmentation and virtual treatment simulation, EDDA Technology aims to improve early disease detection and diagnosis, ultimately enhancing patient outcomes.

NewMed Medical is a Shanghai-based medical device supplier, engaged in developing and procuding interventional artificial heart valve systems.

AnchorDx, also known as Guangzhou Baseline Medical, specializes in high-throughput sequencing technologies and molecular liquid biopsies, offering non-invasive access to genetic information. The company focuses on precision medicine and aims to be a leading global provider of medical solutions by leveraging its expertise in cancer genomics, genetics, and bioinformatics. With a core team possessing over 20 years of industry experience, AnchorDx collaborates with various downstream enterprises, hospitals, and research institutions to create an integrated industrial chain that facilitates the transformation of academic research into clinical products. The company is committed to developing independent intellectual property rights and competitive clinical testing products, thereby providing accurate and comprehensive services to patients, doctors, and medical institutions.

Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on restless leg syndrome. Its innovative device utilizes neural circuitry to alleviate symptoms and promote undisturbed sleep, empowering patients to better manage their chronic medical conditions.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment, primarily serving cancer and cell biology research. The company offers a range of products including the Cytek Aurora and Cytek Northern Lights flow cytometers, the DxP Athena flow cytometry system that utilizes advanced technology to resolve dim populations in a multicolor format, and the QbSure quality control program for assessing cytometer performance. Additionally, Cytek provides proprietary cFluor reagents designed to optimize instrument performance in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company, formerly known as Cytoville, Inc., rebranded to Cytek Biosciences, Inc. in August 2015.

Zylox Medical Device Co. was established in 2012 in Hangzhou by a team of experienced professionals who returned to China after working in prominent medical device companies in the US and Europe. The company specializes in developing innovative interventional and implantable devices for peripheral and neurovascular applications. Its product portfolio includes a range of devices such as PTA balloons, drug-coated PTA balloons, stents, and thrombectomy devices. Zylox is committed to providing high-quality medical solutions aimed at improving patient care and enhancing the capabilities of healthcare professionals. The company continues to expand its product offerings to address various vascular conditions both in China and internationally.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

CoreMap, Inc. is dedicated to enhancing patient outcomes through advanced diagnostic technology tailored for electrophysiologists treating atrial fibrillation. Founded in 2016 and based in Winooski, Vermont, the company has developed a micro-electrode solution that allows for sequential mapping of tissue properties. This innovative technology addresses critical challenges in atrial fibrillation treatment, specifically poor spatial resolution and inadequate sample density. CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even in the presence of fibrillation, thereby enabling medical practitioners to offer more effective treatment options for patients.

NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018, the company utilizes its artificial intelligence-driven oncology pattern recognition algorithm (OPRA) to analyze extensive datasets and uncover novel tumor biology, which aids in the identification of key oncogenes. Erasca's drug development pipeline includes Naporafenib, a pan-RAF inhibitor with potential applications in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors, as well as ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor. The company aims to provide precision oncology options through collaborations with academic and biopharmaceutical partners, ultimately seeking to offer innovative treatment solutions for patients.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.

MobileODT Ltd develops optical diagnostic devices and software services aimed at early cancer detection. The company offers the EVA COLPO, a portable and FDA-cleared colposcope that connects to the internet, making it easy for healthcare providers to conduct examinations. The EVA SANE system allows for the secure management of patient data, including photos and notes, on a HIPAA-compliant server. Additionally, the EVA WELL tool enhances gynecologic exams through digital visualization. MobileODT also provides a mobile application for remote image capture and patient information tracking, alongside a cloud-based portal for collaboration and reporting. Other products include Eviscope, designed for documenting violence and abuse, EviDx for case documentation, and EviCenter for managing patient data. Founded in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has established a strong presence in markets such as the U.S., Africa, and India, having conducted over 40,000 procedures across 29 countries.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.

New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

TytoCare Ltd. is a healthcare technology company based in Netanya, Israel, with an additional office in New York, New York. Founded in 2011, TytoCare develops handheld devices and applications that facilitate on-demand medical examinations and diagnoses through virtual consultations with healthcare providers. Its product offerings include TytoHome for consumers, TytoPro for healthcare professionals, and TytoClinic for remote care locations. These solutions enable users to perform self-examinations of various body systems, including the heart, lungs, skin, and throat, while providing remote access to physicians for evaluation and treatment of common conditions such as ear infections, flu, and respiratory issues. The platform incorporates a cloud-based data repository, analytics, and machine learning algorithms, enhancing the accuracy and user experience of remote healthcare services. TytoCare has established a strategic partnership with Novant Health to further expand its reach in the telehealth market.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

NewMed Medical is a Shanghai-based medical device supplier, engaged in developing and procuding interventional artificial heart valve systems.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.

GrayBug is a pharmaceutical company that develops transformative medicines for ocular diseases. They also develop therapies for inflammatory diseases with unmet needs. Their proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury.

Acutus Medical, Inc. is a company focused on managing cardiac arrhythmias through the development of advanced medical technologies. Founded in 2011 and based in Carlsbad, California, it designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product lineup includes the AcQMap console for advanced imaging, navigation, and mapping, as well as various diagnostic and therapeutic devices such as diagnostic catheters, ablation catheters, and access devices. Acutus Medical's offerings also feature software solutions that enhance mapping accuracy and procedure efficiency. The company collaborates with medical scientists and engineers in the U.S. and Europe to innovate and improve treatment methods for complex cardiac arrhythmias, serving hospitals and electrophysiologists globally.

Acutus Medical, Inc. is a company focused on managing cardiac arrhythmias through the development of advanced medical technologies. Founded in 2011 and based in Carlsbad, California, it designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product lineup includes the AcQMap console for advanced imaging, navigation, and mapping, as well as various diagnostic and therapeutic devices such as diagnostic catheters, ablation catheters, and access devices. Acutus Medical's offerings also feature software solutions that enhance mapping accuracy and procedure efficiency. The company collaborates with medical scientists and engineers in the U.S. and Europe to innovate and improve treatment methods for complex cardiac arrhythmias, serving hospitals and electrophysiologists globally.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

TytoCare Ltd. is a healthcare technology company based in Netanya, Israel, with an additional office in New York, New York. Founded in 2011, TytoCare develops handheld devices and applications that facilitate on-demand medical examinations and diagnoses through virtual consultations with healthcare providers. Its product offerings include TytoHome for consumers, TytoPro for healthcare professionals, and TytoClinic for remote care locations. These solutions enable users to perform self-examinations of various body systems, including the heart, lungs, skin, and throat, while providing remote access to physicians for evaluation and treatment of common conditions such as ear infections, flu, and respiratory issues. The platform incorporates a cloud-based data repository, analytics, and machine learning algorithms, enhancing the accuracy and user experience of remote healthcare services. TytoCare has established a strategic partnership with Novant Health to further expand its reach in the telehealth market.

TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio offers a range of products, including the OviTex Reinforced Tissue Matrix, which is utilized in hernia repair and abdominal wall reconstruction, and the OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically for laparoscopic and robotic-assisted surgical procedures, which are derived from ovine rumen and incorporate polypropylene fiber. The company's marketing efforts are primarily focused in the United States, utilizing a direct sales force to promote its innovative solutions in soft tissue repair.

MobileODT Ltd develops optical diagnostic devices and software services aimed at early cancer detection. The company offers the EVA COLPO, a portable and FDA-cleared colposcope that connects to the internet, making it easy for healthcare providers to conduct examinations. The EVA SANE system allows for the secure management of patient data, including photos and notes, on a HIPAA-compliant server. Additionally, the EVA WELL tool enhances gynecologic exams through digital visualization. MobileODT also provides a mobile application for remote image capture and patient information tracking, alongside a cloud-based portal for collaboration and reporting. Other products include Eviscope, designed for documenting violence and abuse, EviDx for case documentation, and EviCenter for managing patient data. Founded in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has established a strong presence in markets such as the U.S., Africa, and India, having conducted over 40,000 procedures across 29 countries.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic products for pain relief and chronic conditions. The company is known for its PatchPump, a customizable, pre-filled, and pre-programmed disposable delivery platform designed for large volume and viscous formulations. Key offerings include Trevyent, a single-use PatchPump pre-filled with treprostinil for treating pulmonary arterial hypertension, and SMT-201, which enables subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug. Additionally, SMT-301 delivers bupivacaine directly into surgical wounds for effective local pain relief. Founded in 2005 and headquartered in San Ramon, California, with a research and development center in Rehovot, Israel, SteadyMed operates as a subsidiary of United Therapeutics Corporation. The company collaborates with pharmaceutical and device partners to tailor applications of its drug-infusion patches to meet specific therapeutic needs.

Aerpio Pharmaceuticals, a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, is dedicated to developing innovative compounds for treating ocular diseases and diabetic complications. Its lead product candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is working on a bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema through intravitreal injection. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 as a spin-out from Akebia Therapeutics, Aerpio adopts an outsourced approach to pharmaceutical development, leveraging the expertise of its management team.

Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for obstructive sleep apnea (OSA). The company has created the Inspire system, a neurostimulation technology designed to provide safe and effective treatment for moderate to severe OSA. This system employs a proprietary Upper Airway Stimulation (UAS) therapy that utilizes established technologies from cardiac pacing and neurostimulation. Additionally, Inspire is developing a novel closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to keep the airway open. Founded in 2007 and headquartered in Golden Valley, Minnesota, Inspire primarily generates its revenue in the United States, with a growing presence in Europe.

Response Biomedical Corp. specializes in the research, development, and commercialization of rapid diagnostic technologies for various markets, including medical central-lab testing, point of care (POC) testing, and environmental testing. The company operates the RAMP® Platform, which utilizes portable fluorescence immunoassay technology to deliver laboratory-quality results quickly. This platform supports a range of applications, such as early detection of heart conditions, respiratory infections, and environmental hazards. Response Biomedical's tests are designed for use in acute care settings and can be performed using portable devices or compact analyzers. Their products are distributed globally, reaching markets in the United States, Asia, Europe, and beyond. Founded in 1980 and headquartered in Vancouver, Canada, Response Biomedical is committed to providing efficient diagnostic solutions for improved patient management and safety.

GrayBug is a pharmaceutical company that develops transformative medicines for ocular diseases. They also develop therapies for inflammatory diseases with unmet needs. Their proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury.

Acutus Medical, Inc. is a company focused on managing cardiac arrhythmias through the development of advanced medical technologies. Founded in 2011 and based in Carlsbad, California, it designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product lineup includes the AcQMap console for advanced imaging, navigation, and mapping, as well as various diagnostic and therapeutic devices such as diagnostic catheters, ablation catheters, and access devices. Acutus Medical's offerings also feature software solutions that enhance mapping accuracy and procedure efficiency. The company collaborates with medical scientists and engineers in the U.S. and Europe to innovate and improve treatment methods for complex cardiac arrhythmias, serving hospitals and electrophysiologists globally.

UPPER is a biomedicine manufacturing firm. They provide a maya fluoresence analyzer, an ottoman automatic protein analyzer, and other products. Upper Biotech Pharma markets its products.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

TytoCare Ltd. is a healthcare technology company based in Netanya, Israel, with an additional office in New York, New York. Founded in 2011, TytoCare develops handheld devices and applications that facilitate on-demand medical examinations and diagnoses through virtual consultations with healthcare providers. Its product offerings include TytoHome for consumers, TytoPro for healthcare professionals, and TytoClinic for remote care locations. These solutions enable users to perform self-examinations of various body systems, including the heart, lungs, skin, and throat, while providing remote access to physicians for evaluation and treatment of common conditions such as ear infections, flu, and respiratory issues. The platform incorporates a cloud-based data repository, analytics, and machine learning algorithms, enhancing the accuracy and user experience of remote healthcare services. TytoCare has established a strategic partnership with Novant Health to further expand its reach in the telehealth market.

Unilife is a U.S-based medical device and technology company that designs, develops, manufactures and supplies innovative, differentiated delivery systems for injectable drugs and vaccines.

Medigus Ltd. is a medical device company based in Omer, Israel, specializing in minimally invasive endo-surgical tools and direct visualization technology. Established in 1999, Medigus focuses on innovative endoscopic procedures, particularly for the treatment of gastroesophageal reflux disease (GERD), a prevalent chronic condition. The company’s flagship product, the Medigus Ultrasonic Surgical Endostapler (MUSE), is a single-use device designed for the incisionless treatment of GERD. This system integrates a miniaturized video camera, surgical stapler, and ultrasonic alignment technology, allowing gastroenterologists to perform a partial anterior fundoplication without traditional surgical methods, thus transforming GERD treatment. Additionally, Medigus develops a range of micro video cameras under the micro ScoutCam brand, catering to both medical and industrial applications, while also designing endoscopy systems for partner companies based on its proprietary technologies.

Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for obstructive sleep apnea (OSA). The company has created the Inspire system, a neurostimulation technology designed to provide safe and effective treatment for moderate to severe OSA. This system employs a proprietary Upper Airway Stimulation (UAS) therapy that utilizes established technologies from cardiac pacing and neurostimulation. Additionally, Inspire is developing a novel closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to keep the airway open. Founded in 2007 and headquartered in Golden Valley, Minnesota, Inspire primarily generates its revenue in the United States, with a growing presence in Europe.

Keystone Heart aspires to be the world leader in embolic cerebral protection for cardiovascular procedures. To develop and manufacture cerebral protection devices, focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, AF ablation and other structural heart procedures. Cerebral function is the essence of quality of life. Preserving brain reserve throughout medical procedures is a key component to procedural success and patient care.

Whale is a manufacturer specializing in multi-planar surgical imaging and portable diagnostic ultrasound products. The company develops imaging devices that utilize proprietary technologies and advanced manufacturing methods to create safe and efficient systems. These products are designed to enhance the capabilities of surgeons, allowing them to perform procedures with increased speed and ease. By focusing on innovation and user-friendly design, Whale aims to improve surgical outcomes and streamline diagnostic processes in the medical field.

TytoCare Ltd. is a healthcare technology company based in Netanya, Israel, with an additional office in New York, New York. Founded in 2011, TytoCare develops handheld devices and applications that facilitate on-demand medical examinations and diagnoses through virtual consultations with healthcare providers. Its product offerings include TytoHome for consumers, TytoPro for healthcare professionals, and TytoClinic for remote care locations. These solutions enable users to perform self-examinations of various body systems, including the heart, lungs, skin, and throat, while providing remote access to physicians for evaluation and treatment of common conditions such as ear infections, flu, and respiratory issues. The platform incorporates a cloud-based data repository, analytics, and machine learning algorithms, enhancing the accuracy and user experience of remote healthcare services. TytoCare has established a strategic partnership with Novant Health to further expand its reach in the telehealth market.

Unilife is a U.S-based medical device and technology company that designs, develops, manufactures and supplies innovative, differentiated delivery systems for injectable drugs and vaccines.

Domain Surgical is a medical device company that is creating energy-based surgical products for precise soft tissue cutting and coagulation. It creates energy-based equipment used in specialty surgical procedures. Its patent-pending technology produces surface-only tissue effects with energy that does not pass through the patient designed with the surgical staff in mind, for simple user-interface and training. The company manufactures and markets the FMwand Ferromagnetic Surgical System, a hemostatic dissection device that uses pure thermal energy to cut and coagulate soft tissue, without passing an electrical current through the patient. The FMwand imparts as little as 1/10th the amount of thermal injury compared to traditional electrosurgery devices. The FMwand provides fine dissection with a layer-by-layer precision that is unmatched by existing surgical technology.

Seragon Pharmaceuticals, Inc., based in Irvine, California, is a research-focused biopharmaceutical company dedicated to enhancing human and animal health through innovative scientific advancements. The company specializes in the development of orally active selective estrogen receptor degraders (SERDs), particularly targeting metastatic breast cancer. Its lead drug candidate, ARN-810, is currently under evaluation for the treatment of estrogen receptor-positive breast cancer. By leveraging cutting-edge research in metabolism, gene therapy, and bioinformatics, Seragon Pharmaceuticals aims to facilitate access to significant medical breakthroughs, encompassing both clinical applications and consumer products.

Amoy Diagnostics is a research and development based diagnostic company focusing on molecular diagnostics for oncology precision medicine. AmoyDx has a portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx's core product categories include single gene testing kits, multi-gene testing panels, NGS panels, and NGS analytical systems.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Intercept Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases in the United States, Europe, and Canada. Its primary product, Ocaliva, is a farnesoid X receptor agonist approved for the treatment of primary biliary cholangitis (PBC) in adults, often used in combination with ursodeoxycholic acid. The company is also exploring Ocaliva for other conditions, including nonalcoholic steatohepatitis (NASH), and has several additional product candidates in various stages of clinical and preclinical development. Intercept has established partnerships for research and commercialization, including agreements with Sumitomo Dainippon Pharma to develop OCA for PBC and NASH in Japan and China, as well as Aralez Pharmaceuticals Canada to develop bezafibrate in the United States. The company employs various marketing strategies, utilizing an internal commercial team, contract sales organizations, and third-party distributors. Founded in 2002, Intercept Pharmaceuticals is headquartered in New York, New York.

Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

DFine Inc. is a medical device company based in San Jose, California, specializing in minimally invasive therapeutic devices for spinal pathologies, including metastatic spinal tumors and vertebral compression fractures. Founded in 2004, DFine develops advanced solutions such as the STAR tumor ablation system, which offers palliative treatment by ablating malignant lesions in the vertebral body. The company also provides vertebral augmentation systems designed for the percutaneous delivery of bone cement to treat pathological fractures, as well as vertebroplasty systems. In July 2016, DFine became a subsidiary of Merit Medical Systems, Inc., further enhancing its capacity to deliver innovative therapies for spine-related conditions.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

DFine Inc. is a medical device company based in San Jose, California, specializing in minimally invasive therapeutic devices for spinal pathologies, including metastatic spinal tumors and vertebral compression fractures. Founded in 2004, DFine develops advanced solutions such as the STAR tumor ablation system, which offers palliative treatment by ablating malignant lesions in the vertebral body. The company also provides vertebral augmentation systems designed for the percutaneous delivery of bone cement to treat pathological fractures, as well as vertebroplasty systems. In July 2016, DFine became a subsidiary of Merit Medical Systems, Inc., further enhancing its capacity to deliver innovative therapies for spine-related conditions.

Manipal Acunova Ltd. operates as a specialty contract research organization. It provides clinical development services, including project management, clinical development management, biostatistics, medical writing, bio-availability/bio equivalence, and central lab. The company provides bioavailability and bioequivalence services, including regulatory consultancy, volunteer screening, protocol development, pharmacokinetic analysis, adverse event reporting and emergency treatment, data management and statistical analysis, report writing and submission, and specimen storage and archival. It also offers clinical reference laboratory services comprising clinical testing lab for clinical trials, pharmacy company research testing, and patient testing services; and clinical trials and research services, including clinical operations, regulatory strategy and consulting, clinical monitoring, patient recruitment, and supply management services. The company's clinical management services include laboratory data management, SAS programming, ECG core labs, radiology and imaging, coding and dictionary management, pharmacovigilance, and PK/PD analysis. In addition, it provides site management services. The company offers research services for pharmaceutical, biotechnology, device, research, and diagnostic companies in Europe, North America, and Asia. Manipal Acunova Ltd. is based in Bangalore, India with additional offices in Frankfurt, the United Kingdom; Princeton, the United States; Mangalore and Manipal, India; and Moscow, Russia.

Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

Insulet Corporation is a medical device company dedicated to improving the lives of individuals with insulin-dependent diabetes through its innovative Omnipod System. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet develops, manufactures, and markets an insulin delivery system that includes a tubeless, disposable insulin infusion device and a handheld personal diabetes manager. The Omnipod System is designed for ease of use, allowing for automated cannula insertion and smartphone control for dosage management. Insulet primarily sells its products through independent distributors, pharmacy channels, and directly to patients in the United States, Canada, Europe, and the Middle East. Since receiving FDA approval in 2005, the Omnipod System has been adopted by approximately 425,000 insulin-dependent diabetics worldwide, reflecting the company's commitment to enhancing diabetes management.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

Adiana, Inc. is a medical device company based in Redwood City, California, that specializes in the development of permanent contraceptive solutions for women. Founded in 1997, the company focuses on transcervical sterilization systems designed to prevent pregnancy by occluding the fallopian tubes. Its flagship product, Complete TCS, includes a radiofrequency generator, a delivery catheter, and an implantable matrix. This innovative approach offers a non-incisional alternative to traditional tubal ligation, allowing women to avoid the potential side effects and complications associated with other contraceptive methods. As of 2007, Adiana operates as a subsidiary of CYTYC Corp.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

Emphasys Medical develops therapeutic devices for the treatment of patients with emphysema and other breathing disorders. It offers Zephyr Endobronchial Valve system, which is designed to block air from passing through the opening in the lung and into the chest cavity, resulting in the reduction or elimination of airflow through the leak to allow the tissue to heal. Emphasys Medical was founded in 2000 and is based in Redwood City, California.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Molecular Staging, Inc. is a life sciences tool company focused on developing technologies for the detection and measurement of proteins and nucleic acids. Its offerings encompass various applications in proteomics, genomics, pharmacogenomics, and diagnostics. Notable products include protein microarrays, which allow researchers to analyze multiple proteins simultaneously, and whole-genome amplification technology that addresses challenges posed by limited DNA sample quantities. Additionally, the company provides multiplexed diagnostics, facilitating the earlier detection of diseases and enhancing confirmatory diagnoses. Through these innovations, Molecular Staging supports advancements in research and clinical applications.